Jazz Pharmaceuticals
JAZZ
249 hedge funds and large institutions have $4.72B invested in Jazz Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 92 increasing their positions, 91 reducing their positions, and 34 closing their positions.
92% more call options, than puts
Call options by funds: $46.2M | Put options by funds: $24.1M
53% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 34
38% more capital invested
Capital invested by funds: $3.41B → $4.72B (+$1.31B)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
6% more funds holding
Funds holding: 234 → 249 (+15)
1% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 91
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WBC
Westpac Banking Corp
Sydney,
Australia
|
+$326M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.8M |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$50.4M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$28.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$28.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$115M |
| 2 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$55M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$48.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25M |
| 5 |
D.E. Shaw & Co
New York
|
-$23.5M |
JAZZ Hedge Fund Activity: Q3 2013 in Review
249 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2013, worth a combined $4.72B — up 38% from $3.41B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new JAZZ positions and 34 closed out — a net gain of 18 holders — while 92 added to existing stakes and 91 trimmed.
The largest buyer was Westpac Banking Corp, opening a new position worth an estimated $326M. The largest seller was Janus Henderson Investors US, cutting an estimated $115M.
- 249 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2013, up from 234 in Q2 2013.
- Funds reported $4.72B of Jazz Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
- 52 funds opened new Jazz Pharmaceuticals positions in Q3 2013 and 34 closed out, a net change of +18 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2013 was Westpac Banking Corp, an estimated $326M added.
- The largest Jazz Pharmaceuticals seller in Q3 2013 was Janus Henderson Investors US, an estimated $115M sold.
Based on aggregated 13F filings for Q3 2013.